Literature DB >> 22674089

Early steroid withdrawal regimen prevents new-onset diabetes mellitus in old-age recipients after living donor liver transplantation.

Young-Kyu Kim1, Kwang-Woong Lee, Seong Hoon Kim, Seong Yeon Cho, Sung-Sik Han, Sang-Jae Park.   

Abstract

BACKGROUND: Steroid use after liver transplantation is known to increase the risk of new-onset diabetes mellitus (NODM). In this study, we tried to identify a patient subgroup who would benefit with regard to NODM by an early steroid withdrawal regimen (ESWR) after living donor liver transplantation (LDLT)
METHODS: Among 100 adult LDLT patients, 65 were on a conventional immunosuppressive regimen (CIR), and 35 were on an ESWR. With the ESWR, the steroid was tapered off mostly within 7 days with induction of basiliximab in combination with tacrolimus and mycophenolate mofetil (MMF). The CIR was a combination of tacrolimus and steroid. MMF was added in selected patients. Steroid was tapered off 2-6 months after LT. The presence of NODM was investigated cross-sectionally 6 months after LT.
RESULTS: There was no significant difference in terms of acute cellular rejection, sepsis, or death during follow-up. NODM had developed in 13 patients (13 %). Old recipient age (≥ 55) and pretransplant history of hypertension were significant risk factors for NODM. The type of immunosuppression was the single risk factor for NODM in subgroup of old-age recipients (≥ 55 years) on the CIR (hazard ratio 13.34, p = 0.04).
CONCLUSIONS: ESWR can safely reduce the incidence of NODM after LDLT in old-age recipients. Therefore, ESWR should be considered first in old-age recipients undergoing LDLT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22674089     DOI: 10.1007/s00268-012-1661-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  27 in total

1.  Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study.

Authors:  Faouzi Saliba; Mohamed Lakehal; Georges-Philippe Pageaux; Bruno Roche; Claire Vanlemmens; Christophe Duvoux; Jérôme Dumortier; Ephrem Salamé; Yvon Calmus; Didier Maugendre
Journal:  Liver Transpl       Date:  2007-01       Impact factor: 5.799

2.  Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality.

Authors:  S Baid; A B Cosimi; M L Farrell; D A Schoenfeld; S Feng; R T Chung; N Tolkoff-Rubin; M Pascual
Journal:  Transplantation       Date:  2001-09-27       Impact factor: 4.939

3.  Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.

Authors:  M D Stegall; M E Wachs; G Everson; T Steinberg; B Bilir; R Shrestha; F Karrer; I Kam
Journal:  Transplantation       Date:  1997-12-27       Impact factor: 4.939

4.  Early steroid withdrawal after liver transplantation for hepatocellular carcinoma.

Authors:  Zhi-Shui Chen; Fan He; Fan-Jun Zeng; Ji-Pin Jiang; Dun-Feng Du; Bin Liu
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

5.  Predictive factors for posttransplant diabetes mellitus within one-year of liver transplantation.

Authors:  Loubna Oufroukhi; Nassim Kamar; Fabrice Muscari; Laurence Lavayssière; Joëlle Guitard; Davis Ribes; Laure Esposito; Laurent Alric; Hélène Hanaire; Lionel Rostaing
Journal:  Transplantation       Date:  2008-05-27       Impact factor: 4.939

6.  Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy.

Authors:  Shin Hwang; Sung-Gyu Lee; Chul-Soo Ahn; Ki-Hun Kim; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Jung-Ik Park; Je-Ho Ryu; Hyo-Jun Lee; Dong-Jin Suh; Young-Suk Lim
Journal:  Liver Transpl       Date:  2008-06       Impact factor: 5.799

Review 7.  Diabetes mellitus, part 1: physiology and complications.

Authors:  Muralitharan Nair
Journal:  Br J Nurs       Date:  2007 Feb 8-21

8.  Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors.

Authors:  N B Sumrani; V Delaney; Z K Ding; R Davis; P Daskalakis; E A Friedman; K M Butt; J H Hong
Journal:  Transplantation       Date:  1991-02       Impact factor: 4.939

9.  Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.

Authors:  Chi Leung Liu; Sheung Tat Fan; Chung Mau Lo; See Ching Chan; Irene O Ng; Ching Lung Lai; John Wong
Journal:  Liver Transpl       Date:  2004-06       Impact factor: 5.799

10.  Posttransplant diabetes mellitus in liver transplant recipients.

Authors:  Carolyn J Driscoll; Ann K Cashion; Donna K Hathaway; Carol Thompson; Yvette Conley; Osama Gaber; Santiago Vera; Hosein Shokouh-Amiri
Journal:  Prog Transplant       Date:  2006-06       Impact factor: 1.065

View more
  7 in total

1.  New-Onset Diabetes Mellitus After Transplantation in a Cynomolgus Macaque (Macaca fasicularis).

Authors:  Kristin A Matthews; Makoto Tonsho; Joren C Madsen
Journal:  Comp Med       Date:  2015-08       Impact factor: 0.982

2.  New-onset diabetes mellitus after living-donor liver transplantation: association with graft synthetic function.

Authors:  Shintaro Yagi; Toshimi Kaido; Taku Iida; Atsushi Yoshizawa; Hideaki Okajima; Shinji Uemoto
Journal:  Surg Today       Date:  2016-11-11       Impact factor: 2.549

3.  New-onset diabetes after adult liver transplantation in the Korean Organ Transplantation Registry (KOTRY) study.

Authors:  Jong Man Kim; Shin Hwang; Kwang-Woong Lee; Jae-Geun Lee; Je Ho Ryu; Bong-Wan Kim; Dong Lak Choi; Young Kyoung You; Dong-Sik Kim; Yang Won Nah; Koo Jeong Kang; Jai Young Cho; Geun Hong; In Seok Choi; Hee Chul Yu; Dongho Choi; Myoung Soo Kim
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

4.  The need for deepened molecular mechanism exploration in new onset diabetes after transplantation (NODAT).

Authors:  Ke Zhang; Shusen Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

Review 5.  New-Onset Diabetes Mellitus (NODM) After Liver Transplantation (LT): The Ultimate Non-diabetogenic Immunosuppressive Therapy.

Authors:  Ali R Chaitou; Surbhi Valmiki; Mrinaal Valmiki; Maria Zahid; Mohamed A Aid; Peter Fawzy; Safeera Khan
Journal:  Cureus       Date:  2022-03-29

Review 6.  Expert consensus on management of metabolic disease in Chinese liver transplant recipients.

Authors:  Tian Shen; Li Zhuang; Xiao-Dong Sun; Xiao-Sheng Qi; Zhi-Hui Wang; Rui-Dong Li; Wen-Xiu Chang; Jia-Yin Yang; Yang Yang; Shu-Sen Zheng; Xiao Xu
Journal:  World J Gastroenterol       Date:  2020-07-21       Impact factor: 5.742

Review 7.  Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment.

Authors:  Maria J Peláez-Jaramillo; Allison A Cárdenas-Mojica; Paula V Gaete; Carlos O Mendivil
Journal:  Diabetes Ther       Date:  2018-02-06       Impact factor: 2.945

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.